Compare McKesson Corporation (MCK) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs ABRDN Physical Gold Shares ETF — how do they compare? McKesson Corporation trades at $823.64 (market cap $97.35B), while ABRDN Physical Gold Shares ETF trades at $38.77. The key difference: McKesson Corporation pays a 0.39% dividend while ABRDN Physical Gold Shares ETF pays none, and McKesson Corporation is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| MCK | SGOL | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $995.69 | $51.41 |
52-Week Low | $659.01 | $31.18 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
SGOL is trading at $38.16, down 0.16% with a bearish technical outlook indicated by 16 sell signals against 0 buy signals. The stock faces pressure from higher interest rate expectations and dollar strength, though central bank gold buying provides structural support. Recent trading has tested key support levels around $38 with resistance forming at $39.
The outlook remains cautious with technical indicators signaling bearish momentum and fundamental data limited. Investment opportunities exist for long-term gold exposure, but risks include Fed policy uncertainty and dollar volatility. Near-term direction depends on gold's ability to hold $4,000/oz support amid competing macroeconomic forces.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
